Journal
Neuromuscular Disorders
Publication Date
2-1-2023
Volume
33
Issue
2
First Page
199
Last Page
207
Document Type
Open Access Publication
DOI
10.1016/j.nmd.2023.01.001
Rights and Permissions
Moore U, Fernández-Simón E, Schiava M, Cox D, Gordish-Dressman H, James MK, Mayhew A, Wilson I, Guglieri M, Rufibach L, Blamire A, Carlier PG, Mori-Yoshimura M, Day JW, Jones KJ, Bharucha-Goebel DX, Salort-Campana E, Pestronk A, Walter MC, Paradas C, Stojkovic T, Bravver E, Pegoraro E, Mendell JR, Bushby K, Diaz-Manera J, Straub V; Jain COS Consortium. Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy. Neuromuscul Disord. 2023 Feb;33(2):199-207. doi: 10.1016/j.nmd.2023.01.001. © 2023 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Recommended Citation
Moore, Ursula; Pestronk, Alan; and et al., "Myostatin and follistatin as monitoring and prognostic biomarkers in dysferlinopathy." Neuromuscular Disorders. 33, 2. 199 - 207. (2023).
https://digitalcommons.wustl.edu/oa_4/2399
Department
ICTS (Institute of Clinical and Translational Sciences)
Additional Links
Supplemental material is available for this article at publisher site.
